Autonomix Medical, Inc. 8-K

What Happened
Autonomix Medical, Inc. (AMIX) filed an 8‑K on January 9, 2026 under Regulation FD to announce new subgroup clinical data from its proof‑of‑concept (PoC) study. The data, presented at the 2026 ASCO Gastrointestinal Cancers Symposium, reportedly demonstrate rapid, durable and meaningful pain relief in pancreatic cancer patients across all disease stages. The company said this analysis expands on previously reported results and examines outcomes by pancreatic cancer stage in patients treated for severe pancreatic cancer‑related pain. Autonomix attached a press release (Exhibit 99.1) and posted an updated corporate presentation (Exhibit 99.2) on its website.

Key Details

• Date of disclosure: January 9, 2026 (Regulation FD filing).
• Event where data presented: 2026 ASCO Gastrointestinal Cancers Symposium.
• Focus: subgroup analysis of ongoing PoC clinical evaluation for severe pancreatic cancer‑related pain, by cancer stage.
• Materials made public: press release and updated investor/corporate presentation posted on the company website.

Why It Matters
This disclosure updates investors on clinical progress for Autonomix’s therapy in a high‑need indication—severe pancreatic cancer pain—highlighting subgroup results across disease stages. While the filing does not include financial or efficacy numeric details in the 8‑K text itself, the press release and presentation may contain data that could influence clinical and commercial expectations. Investors should review the attached press release and updated presentation for the full data and consider follow‑up announcements or regulatory/clinical updates for quantitative results.